Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly (NYSE: LLY) announced that all three of the largest U.S. PBMs will cover its full obesity medicine portfolio, Foundayo and Zepbound, expanding access to FDA-approved treatments.
CVS Caremark coverage for Foundayo starts June 1, 2026, with broader Zepbound coverage by October 1. Eligible commercially insured patients may pay as low as $25 per month, while certain Medicare Part D beneficiaries may pay $50 per month via the GLP-1 Bridge program starting July 1.
Eli Lilly (NYSE:LLY) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, will join a fireside chat at 3:20 p.m. Eastern time.
A live audio webcast and a 90-day replay will be available on Lilly's investor website in the Webcasts & Presentations section.
Lilly (NYSE:LLY) agreed to acquire three companies—Curevo, LimmaTech Biologics and Vaccine Company—to expand its infectious disease portfolio focused on prevention.
Deals include up to $1.5B for Curevo, $780M for LimmaTech and $1.55B for Vaccine Company, adding late-stage shingles, early-stage bacterial and preclinical viral vaccine platforms.
Lilly (NYSE: LLY) reported interim Phase 1b Heart-2 data for VERVE-102, an investigational in vivo base editor targeting PCSK9 in adults with HeFH or premature CAD. In 35 participants, a single intravenous dose produced dose-dependent mean PCSK9 reductions of 51–88% and LDL-C reductions up to 62%, sustained for up to 18 months. VERVE-102 was reported as well tolerated, with no treatment-related serious adverse events or dose-limiting toxicities. The FDA granted Fast Track designation for VERVE-102 in hyperlipidemia with high cardiovascular risk, and Lilly plans to start a Phase 2 study by year-end.
Lilly (NYSE:LLY) will showcase an extensive oncology portfolio at the 2026 ASCO Annual Meeting from May 29–June 2 in Chicago. Highlights include Plenary Session presentations on Phase 3 data for Retevmo in RET fusion-positive NSCLC and Verzenio in advanced dedifferentiated liposarcoma.
Additional sessions feature first clinical results for an investigational Nectin-4–targeting ADC, multiple lung and blood cancer programs, and updated Phase 1 data on KLN-1010, an in vivo BCMA CAR-T from Kelonia Therapeutics, which Lilly has agreed to acquire, pending customary approvals.
Lilly (NYSE: LLY) reported topline Phase 3 TRIUMPH-1 results for investigational triple agonist retatrutide in adults with obesity or overweight without diabetes. At 80 weeks, retatrutide 12 mg cut body weight by 28.3% (70.3 lbs), 9 mg by 25.9%, and 4 mg by 19.0%, all versus 2.2% on placebo.
At 104 weeks in an extension (BMI ≥35), 12 mg achieved 30.3% (85.0 lbs) average weight loss. A high share reached ≥25–35% loss and BMI <30. Retatrutide also improved several cardiometabolic risk factors, with gastrointestinal events and some sensory and urinary events more frequent than placebo.
Lilly (NYSE: LLY) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, chief scientific and product officer and president of Lilly Research Laboratories, will join a fireside chat at 1:30 p.m. Eastern time.
A live audio webcast and a 90-day replay will be available on Lilly's investor website under "Webcasts & Presentations".
Lilly (NYSE: LLY), the Caitlin Clark Foundation, and Musco Lighting opened three new multi-sport community courts across Indianapolis, expanding year-round access to safe play spaces for youth.
Sites include two Indianapolis Public Schools courts and a new downtown park and court Lilly is providing to the City and Indy Parks for its 150th anniversary.
Lilly (NYSE:LLY) and UNICEF USA launched a six-year NCD initiative (2026–2032) targeting over 30 million children and caregivers in 21 low- and middle-income countries.
Lilly will commit $50 million to strengthen primary healthcare systems, focusing on prevention, early diagnosis and long-term care for childhood non-communicable diseases and obesity.
Lilly (NYSE: LLY) reported late-phase results showing people with obesity largely maintained prior weight loss when switching from higher-dose injectable incretin therapy to Foundayo or lower-dose Zepbound.
After about one year, participants regained only 0.9–5.6 kg on average, with safety profiles consistent with earlier Phase 3 studies.